Results 301 to 310 of about 333,295 (341)

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations

Seminars in Thrombosis and Hemostasis, 2016
R. Marlar, B. Clément, J. Gausman
semanticscholar   +1 more source

The Partial Thromboplastin Time (Cephalin Time) in Anticoagulation Therapy

American Journal of Clinical Pathology, 1962
Gerd P. Struver, Donald L. Bittner
openaire   +3 more sources

Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.

Methods in molecular biology, 2017
G. Kershaw
semanticscholar   +1 more source

Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011).

Journal of Veterinary Emergency and Critical Care, 2016
Jennifer Song, K. Drobatz, Deborah C Silverstein   +2 more
semanticscholar   +1 more source

Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time

Thrombosis and Haemostasis, 2016
C. Keyl, Cornelius Lehane, E. Zimmer, D. Trenk   +3 more
semanticscholar   +1 more source

Heparin and the Activated Partial Thromboplastin Time

American Journal of Clinical Pathology, 1979
openaire   +3 more sources

Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban

International Journal of Laboratory Hematology, 2015
Susan Guy, Steve Kitchen, R. Maclean, J. J. V. Veen   +3 more
semanticscholar   +1 more source

Activated Partial Thromboplastin Time Evaluation

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
openaire   +3 more sources

Comparison of Anti-Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Patients With Cirrhosis

Therapeutic Drug Monitoring, 2015
A. Fuentes, S. Gordon-Burroughs, Jeffrey B. Hall, D. Putney, H. Monsour   +4 more
semanticscholar   +1 more source